BioSpace News Archive

The College Sports Information Directors of America (CoSIDA) in association with The Associated Press (AP) and the Fiesta Bowl Organization, will recognize college football players who have overcome adversity with a new honor, the Mayo Clinic Comeback Player of the Year Award

Stryker’s Spine division will feature its family of 3D-printed Tritanium interbody fusion cages and highlight its Tritanium In-Growth Technology1 in an augmented reality experience at the North American Spine Society Annual Meeting, Sept. 26–29, 2018, in Los Angeles (booth No. 1401).

AIVITA Biomedical announced today that it has dosed its first of 10 patients currently enrolled as part of its Phase 2 trial in patients with advanced ovarian cancer.

Florida medical marijuana clinic, CannaMD, continues statewide expansion with the opening of its new Sarasota location (6151 Lake Osprey Drive, Suite 300, Sarasota, FL 34240). This marks the 13th opening for the rapidly expanding clinic, as well as a welcome change for Sarasota County residents:

New drug discovery has been limited by researchers’ inability to control a molecules’ 3D structure. But a team of scientists from The Graduate Center of The City University of New York (GC/CUNY) has made a breakthrough in chemical synthesis that now makes it possible to quickly and reliably modify a molecule’s 3D structure, according to a paper in Friday’s issue of Science.

Canadians should not buy or use health products that contain 2,4-dinitrophenol, more commonly known as DNP, because it is toxic and can cause death.

International Medical Corps and Children’s Health Fund are working together to help communities affected by the catastrophic flooding in the Carolinas caused by Hurricane Florence

Array BioPharma, Inc. (NASDAQ: ARRY) today announced that the European Commission (EC) has approved BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test.

Any discussion involving “precision” in healthcare typically revolves around the use of precision medicine based on a patient’s genetic profile. However, in a commentary in the September issue of The American Journal of Managed Care®, authors Dhruv Khullar, MD, MPP, and Rainu Kaushal, MD, MPH, say there’s a different way that precision can be employed to better care for high-need, high-cost (HNHC) patients.

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) resulting from allegations that AbbVie and/or its executives may have issued materially misleading business information to the investing public.